"Receptors, Progesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
| Descriptor ID |
D011980
|
| MeSH Number(s) |
D12.776.826.750.765
|
| Concept/Terms |
Receptors, Progesterone- Receptors, Progesterone
- Progesterone Receptor
- Receptor, Progesterone
- Progestin Receptors
- Receptors, Progestin
- Progesterone Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Progesterone".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Progesterone".
This graph shows the total number of publications written about "Receptors, Progesterone" by people in this website by year, and whether "Receptors, Progesterone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 3 | 3 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 3 | 5 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 4 | 6 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 6 | 6 |
| 2013 | 1 | 5 | 6 |
| 2014 | 4 | 4 | 8 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 4 | 7 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 7 | 9 |
| 2019 | 6 | 3 | 9 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 3 | 4 |
| 2025 | 2 | 6 | 8 |
| 2026 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Glob Oncol. 2026 May; 12(5):e2500705.
-
Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e520518.
-
Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Age 70 or Older with Hormone Receptor-Positive (HR+) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS): Review of Historical Performance. Ann Surg Oncol. 2026 Jun; 33(6):5524-5532.
-
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data. Clin Cancer Res. 2026 Jan 16; 32(2):428-437.
-
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 12 01; 8(12):e2549109.
-
Emerin expression stratification across breast cancer subtypes. Cancer Treat Res Commun. 2025; 45:101037.
-
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer. Ann Oncol. 2025 11; 36(11):1356-1365.
-
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial. Ann Surg Oncol. 2025 Oct; 32(11):8113-8126.
-
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.